Compare Alligator Bioscience AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 106 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-7.73
-1,096.66%
15.43
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Dec 2025)
Net Profit:
-29 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-49.56%
0%
-49.56%
6 Months
-87.84%
0%
-87.84%
1 Year
-91.94%
0%
-91.94%
2 Years
-99.26%
0%
-99.26%
3 Years
-98.32%
0%
-98.32%
4 Years
-99.42%
0%
-99.42%
5 Years
-99.79%
0%
-99.79%
Alligator Bioscience AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-34.86%
EBIT Growth (5y)
2.92%
EBIT to Interest (avg)
-108.20
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
-0.43
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-5.39
EV to EBIT
-0.79
EV to EBITDA
-1.01
EV to Capital Employed
-2.76
EV to Sales
3.77
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
0.00
0.50
-100.00%
Operating Profit (PBDIT) excl Other Income
-22.60
-17.00
-32.94%
Interest
9.30
4.60
102.17%
Exceptional Items
2.80
8.90
-68.54%
Consolidate Net Profit
-29.00
-12.30
-135.77%
Operating Profit Margin (Excl OI)
-498,000.00%
-36,993.60%
-46,100.64%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -100.00% vs 0.00% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -135.77% vs -623.53% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
0.50
57.80
-99.13%
Operating Profit (PBDIT) excl Other Income
-122.00
-182.40
33.11%
Interest
44.30
19.70
124.87%
Exceptional Items
99.40
0.00
Consolidate Net Profit
-51.30
-233.90
78.07%
Operating Profit Margin (Excl OI)
-217,381.30%
-4,000.30%
-21,338.10%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -99.13% vs -0.52% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 78.07% vs 5.91% in Dec 2024
About Alligator Bioscience AB 
Alligator Bioscience AB
Pharmaceuticals & Biotechnology
Alligator Bioscience AB is a Sweden-based company that is engaged in development of immunotherapies for the treatment of cancer. The Company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. In the discovery of those drugs, the Company uses its technology platforms ALLIGATOR-GOLD and FIND. ALLIGATOR-GOLD is a library containing human antibodies. FIND (which stands for Fragment Induced Diversity) is an antibody optimization technology. In its pipeline, the Company has thee projects: ADC-1013 (antibody), ATOR-1015 (bispecific immune activating antibody) and ATOR-1016 (bispecific agonistic antibody), which are in research/preclinical stage.
Company Coordinates 
Company Details
Scheelevagen 2 Byggnad 401 , LUND None : 223 63
Registrar Details






